This study is not yet accepting patients
Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma
Summary
- Eligibility
- for people ages 3-21 (full criteria)
- Location
- at San Francisco, California
- Dates
- study startedestimated completion
- Principal Investigator
- by Sabine Mueller, MD, PhD, MASHideho Okada, MD, PhD
Description
Summary
Official Title
Details
Keywords
Eligibility
Location
Lead Scientists at UCSF
- Sabine Mueller, MD, PhD, MAS
Professor, Neurology, School of Medicine - Hideho Okada, MD, PhD
Dr. Okada is a creative physician-scientist who has developed therapeutic modalities in the laboratory, translated them into clinical protocols, and used his expertise as both scientist and clinician to assess the clinical data from ongoing trials. Dr. Okada's work has consistently focused on immunotherapeutic strategies aimed at a daunting challenge in oncology – malignant brain tumors.
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- University of California, San Francisco
- ID
- NCT05478837
- Phase
- Phase 1 Glioma Research Study
- Study Type
- Interventional
- Participants
- Expecting 12 study participants
- Last Updated